Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, INC. director Heather C Getz reported an open-market purchase of company stock. On March 16, 2026, she bought 20,000 shares of Myomo common stock at $0.6986 per share, in a single open-market transaction. Following this trade, her direct ownership increased to 131,754 shares of common stock.
MYOMO, INC. director Kirk Thomas F reported an open-market purchase of 72,000 shares of Common Stock. The weighted average purchase price was about $0.7099 per share, with individual trade prices ranging from $0.70 to $0.71. Following these purchases, he directly owns 553,857 shares.
MYOMO, INC. director Heather C. Getz made an open-market purchase of 70,000 shares of common stock at a weighted average price of $0.728 per share. The trades were executed in multiple lots between $0.72 and $0.73 per share.
Following this transaction, she directly owns 111,754 shares of MYOMO common stock. The filing describes these transactions as open-market purchases, indicating she used personal capital to increase her direct equity position in the company.
Myomo, Inc. is a wearable medical robotics company focused on its MyoPro myoelectric upper-limb orthosis, sold mainly through direct billing to patients and their insurers. Revenue grew 26% in 2025 as the company improved cycle times and moved more units from authorization to delivery within each period.
The reimbursement pipeline reached 1,528 patients as of December 31, 2025, up 10% year over year, while backlog declined to 199 MyoPro units, down 27% as cases converted to revenue. Myomo relies heavily on Medicare: patients with Medicare Part B accounted for 54% of total revenue in 2025, and Medicare Advantage plans 20% of product revenue.
CMS pays lump-sum fees under brace codes L8701 and L8702, with 2026 schedule amounts of about $34,970 for Motion W and $68,800 for Motion G. Despite revenue growth, Myomo reported a 2025 net loss of $15.6 million versus $6.2 million in 2024, with an accumulated deficit of about $118.1 million and $18.4 million of cash, cash equivalents and short-term investments at year-end. As of March 2, 2026, 38,511,715 shares of common stock were outstanding.
Myomo, Inc. is a wearable medical robotics company focused on its MyoPro myoelectric upper-limb orthosis, sold mainly through direct billing to patients and their insurers. Revenue grew 26% in 2025 as the company improved cycle times and moved more units from authorization to delivery within each period.
The reimbursement pipeline reached 1,528 patients as of December 31, 2025, up 10% year over year, while backlog declined to 199 MyoPro units, down 27% as cases converted to revenue. Myomo relies heavily on Medicare: patients with Medicare Part B accounted for 54% of total revenue in 2025, and Medicare Advantage plans 20% of product revenue.
CMS pays lump-sum fees under brace codes L8701 and L8702, with 2026 schedule amounts of about $34,970 for Motion W and $68,800 for Motion G. Despite revenue growth, Myomo reported a 2025 net loss of $15.6 million versus $6.2 million in 2024, with an accumulated deficit of about $118.1 million and $18.4 million of cash, cash equivalents and short-term investments at year-end. As of March 2, 2026, 38,511,715 shares of common stock were outstanding.
Myomo, Inc. reported fourth quarter 2025 revenue of $11.4 million, down 6% from 2024, while full-year 2025 revenue grew 26% to $40.9 million. Q4 gross margin was 68.6%, and full-year gross margin was 65.7%, both below 2024 levels.
The company’s net loss widened to $3.8 million in Q4 2025 and $15.6 million for the year, compared with losses of $0.3 million and $6.2 million in 2024. Cash, cash equivalents and short-term investments totaled $18.4 million as of December 31, 2025.
Recurring patient sources, including O&P providers and referrals from the MyoConnect program, accounted for 42% of Q4 revenue versus 26% a year earlier, supported by a record 241 MyoPro orders. For 2026, Myomo expects revenue of $43 million to $46 million and aims to cut negative free cash flow by roughly half compared with 2025.
Myomo, Inc. reported fourth quarter 2025 revenue of $11.4 million, down 6% from 2024, while full-year 2025 revenue grew 26% to $40.9 million. Q4 gross margin was 68.6%, and full-year gross margin was 65.7%, both below 2024 levels.
The company’s net loss widened to $3.8 million in Q4 2025 and $15.6 million for the year, compared with losses of $0.3 million and $6.2 million in 2024. Cash, cash equivalents and short-term investments totaled $18.4 million as of December 31, 2025.
Recurring patient sources, including O&P providers and referrals from the MyoConnect program, accounted for 42% of Q4 revenue versus 26% a year earlier, supported by a record 241 MyoPro orders. For 2026, Myomo expects revenue of $43 million to $46 million and aims to cut negative free cash flow by roughly half compared with 2025.
Myomo, Inc. received an amended Schedule 13G from investment firm Rosalind Advisors, Inc., its fund Rosalind Master Fund L.P., and principals Steven Salamon and Gilad Aharon. They report beneficial ownership of 3,839,772 Myomo common shares, or about 9.99%, based on 38,435,524 shares outstanding as of November 3, 2025.
The group also holds pre-funded warrants for an additional 3,763,258 shares, but a 9.99% ownership blocker prevents exercising these warrants while their stake is at that level. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Myomo.
Myomo, Inc. reported that Chief Executive Officer and director Paul R. Gudonis received a grant of 11,637 shares of common stock on January 12, 2026 at a price of $0 per share. After this grant, he beneficially owned 1,260,650 shares of Myomo common stock in direct form.
The shares represent Restricted Stock Units under a Board-approved program that allows employees to forego 10% of their salary in exchange for RSUs with a grant date fair value of 115% of the salary exchanged. This particular grant covers three months of salary, and the RSUs vest in full on April 12, 2026.
Myomo, Inc. reported a new equity award to its Chief Financial Officer, David A. Henry. On January 12, 2026, he acquired 8,727 shares of common stock at a stated price of $0 per share, increasing his total beneficial ownership to 436,627 shares held directly.
According to the footnote, the award represents Restricted Stock Units granted under a Board-approved program that allows employees to forego 10% of their salary in exchange for RSUs with a grant date fair value of 115% of the salary exchanged. This particular grant covers three months of salary and the RSUs vest in full on April 12, 2026.
Myomo, Inc. received a significant ownership disclosure from Horton Capital affiliates and Joseph M. Manko, Jr. They report beneficial ownership of 1,960,212 common shares, or approximately 5.1% of Myomo’s outstanding stock, based on 38,435,524 shares as of November 3, 2025. The position was acquired by Horton Capital Partners Fund, LP for an aggregate purchase price of about $3,311,165, using working capital.
The investors state they bought the shares because they viewed them as undervalued and as an attractive investment. They indicate they may buy more or sell shares depending on market conditions and Myomo’s performance. The group is actively engaging with Myomo’s management, board, other shareholders, and third parties on topics such as strategy, capital structure, and governance.
Horton Capital submitted a shareholder proposal for Myomo’s 2026 annual meeting, requesting that the board eliminate its classified structure so that all directors are elected annually beginning at or after the 2026 meeting, signaling a focus on board governance and shareholder influence.